

Electronic Annex 2: Details on the drug-resistance profile of 658 patients enrolled in the study

Resistance pattern		Pulmonary	Pulmonary + Extra-pulmonary	Extra-pulmonary
MDR/RR-TB 161/658 (24.5%)	<i>MDR n=153*</i>	137	12	4
	<i>Xpert R-resistant n=8[§]</i>	7	1	-
Pre-XDR-TB 224/658 (34%)	<i>MDR+FQ n=125</i>	121	3	1
	<i>MDR+Inj n=99</i>	92	5	2
XDR-TB 254/658 (38.6%)**		237	15	2
Other (DST) 19/658 (2.9%)	<i>Susceptible n=3[¶]</i>	3	-	-
	<i>R-monoresistant n=4</i>	3	-	1
	<i>R+Other (not H) n=2</i>	1	1	-
	<i>H-monoresistant n=1</i>	1	-	-
	<i>H+Other (not R) n=8</i>	8	-	-
	<i>Polyresistant n=1</i>	1	-	-
TOTAL	658 (100%)	611/658 (92.9%)	37/658 (5.6%)	10/658 (1.5%)

*3 MDR strain of the index case

§5 Xpert R-resistant+FQ

**2 XDR index case

¶2 second-line regimen because of adverse events (AEs) of first-line drugs, 1 second-line regimen per clinical decision

Legend: TB: tuberculosis; MDR: multidrug-resistant; XDR: extensively drug-resistant; RR: rifampicin-resistant; Inj: injectables; H: isoniazid; R: rifampicin; DST: drug susceptibility testing; FQ: fluoroquinolone